This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，C 端酰胺化 |
| 分子量 | 约 711.85 g/mol | 游离碱形式 |
| 外观 | 白色至类白色冻干粉 | 研究用材料的常见形态 |
| 溶解性 | 溶于水及 DMSO 等极性溶剂 | 建议现配现用 |
| 储存温度 | -20 °C 或更低 | 干燥、避光、限制冻融次数 |
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
==== Physiological action ==== The physiological effects of labetalol when administered acutely (intravenously) are not predictable solely by their receptor blocking effect, i.e. blocking β1-adrenergic receptors should decrease heart rate, but labetalol does not. When labetalol is given in acute situations, it decreases the peripheral vascular resistance and systemic blood pressure while having little effect on the heart rate, cardiac output and stroke volume, despite its α1-, β1- and β2-adrenergic receptor blocking mechanism. These effects are mainly seen when the person is in the upright position. Long term labetalol use also has different effects from other beta blockers. Other beta blockers, such as propranolol, persistently reduce cardiac output during exercise. The peripheral vascular resistance decreases when labetalol is first administered. Continuous labetalol use further decreases peripheral vascular resistance. However, during exercise, cardiac output remains the same due to a compensatory mechanism that increases stroke volume. Thus, labetalol is able to reduce heart rate during exercise while maintaining cardiac output by the increase in stroke volume.
== Toxicity == Toxicity data in humans are limited, although laboratory studies indicate that certain compounds in the bark and roots or their extracts may cause adverse effects when consumed in excess. Supplementation with M. oleifera leaf extract is potentially toxic at levels exceeding 3,000 mg/kg of body weight, but safe at levels below 1,000 mg/kg. A study on albino mice found that high levels (>5,000mg/kg) of consumption could impair renal function. M. oleifera may interfere with prescription drugs affecting cytochrome P450 (including CYP3A4) and may inhibit the antihyperglycemic effect of sitagliptin. In November 2025, Food Standards Australia New Zealand (FSANZ) rejected an application to approve Moringa oleifera leaves, immature pods, and oil as a novel food. The decision cited insufficient evidence to confirm its safety for human consumption as a food. As a result (confirmed in May 2026 via Department of Agriculture notices), Moringa is not permitted as food or a food ingredient for retail sale in Australia.
Signals also represented a drastic stylistic transformation apart from instrumental changes. The album contained Rush's biggest hit single, "New World Man", while other more experimental songs such as "Digital Man", "The Weapon", and "Chemistry" expanded the band's use of ska, reggae, and funk. The second single, "Subdivisions" reached No. 36 in Canada and No. 5 on the US Album Rock Tracks Chart. Both singles reached the Top 50 in the UK. Signals became the group's second No. 1 album in Canada, their third straight No. 3 album in the UK, and peaked at No. 10 in the US, while continuing their moderate success in the Netherlands, Sweden and Norway, making the Top 30 in each country. Although the band members consciously decided to move in this overall direction, creative differences between the band and longtime producer Terry Brown began to emerge. The band felt dissatisfied with Brown's studio treatment of Signals, while Brown was becoming more uncomfortable with the increased use of synthesizers. Ultimately, Rush and Brown parted ways in 1983, and the experimentation with new electronic instruments and varying musical styles would come into further play on their next studio album. The style and production of Signals were augmented and taken to new heights on Grace Under Pressure (1984). Peart named the album, as he borrowed the words of Ernest Hemingway ("Courage is grace under pressure") to describe what the band had to go through after making the decision to leave Brown.
The EPRDF capitalized on the mismanaged PDRE's weakening state and general unpopularity when rebel forces officially seized power from the PRDE in May 1991. Soon after the EPRDF secured the nation's capital, a "National Conference on Peace and Reconciliation" was called in Addis Ababa. Held in July 1991, the conference was intended to outline a transitional framework for the period following the newest regime change. Some notable ethnicity-based political movements that were present include the Oromo Liberation Front, the Afar Liberation Front, and the Western Somali Liberation Front. Any political organizations that wanted to attend was required to be centered around ethnic identity; thus, several organizations were quickly created for that purpose, resulting in the rapid development of urban elite-led ethnicity-based movements. Any person or political organization that had been associated with Mengistu Haile Mariam's Workers' Party of Ethiopia was also not permitted to attend.
Sources: en.wikipedia.org
=== Zubrin's planet mastery === In Entering Space: Creating a Spacefaring Civilization, Robert Zubrin suggests another form: his definition of a Type I civilization is described as one that has achieved full mastery of the resources of its planet (global), a Type II of its solar system (interplanetary), and a Type III would have unleashed the full potential of the galaxy (starfaring civilization). Metrics other than pure energy consumption have also been proposed. He ponders the possibility of a Type IV civilization, one that would dominate the universe, noting that there are limits to how minds can connect and interact on a galactic or intergalactic basis. As an example, he mentions that communication from the Galactic Center of the Milky Way galaxy to its edge would take about 50,000 years (since nothing can travel faster than light, according to our understanding of physics).
== Classification == Hypermobility spectrum disorders are diagnosed when individuals have symptomatic joint hypermobility but do not meet the criteria for other connective tissue disorders, such as Ehlers–Danlos syndrome. In March 2017, the International Consortium on the Ehlers-Danlos Syndromes published a revised classification naming two syndromes: hypermobile EDS (hEDS), which has narrowly defined criteria, and hypermobility spectrum disorder (HSD) for those with some but not all the features of hEDS. This reclassification aimed to address the overlap between joint hypermobility syndrome and what was previously termed EDS-hypermobile type (EDS-HT). Patients who have a diagnosis of EDS-HT or JHS will fall into one of these two new categories. Hypermobility spectrum disorder does not include people with asymptomatic hypermobility or people with double-jointedness but no other symptoms. Hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders may be equally severe. HSD is further classified into different subtypes, which include:
An acid dye is a dye that is typically applied to a textile at low pH. They are mainly used to dye wool, not cotton fabrics. Some acid dyes are used as food colorants, and some can be used to stain organelles for medical microscopy. Acid dyes are anionic, soluble in water and are essentially applied from acidic bath. They possess acidic groups, such as SO3H and COOH and are applied on wool, silk and nylon when an ionic bond is established between a protonated –NH2 group of the fibre and acid group of the dye. Overall wash fastness is poor, although lightfastness is quite good. As dye and fibre contain opposite electrical natures, strike rate and uptake of acid dye on these fibres is faster; electrolyte at higher concentration is added to retard dye uptake and to form levelled shades. Acid generates cations on fibre and temperature helps to substitute the negative part of the acid with anionic dye molecules.
Sources: en.wikipedia.org
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。
公开资料中它主要以研究用肽的形式出现，未获主要监管机构批准用于治疗。可得材料通常标注仅供研究使用。任何临床用途的宣称都缺少监管依据。
序列中的 Aib 与 D-2-Nal 等非天然残基可提高对肽酶的抵抗能力，并影响受体结合的构象。这类修饰在合成肽设计中较为常见。它们也使常规氨基酸分析需要额外步骤才能确认序列。
Aib 即 α-氨基异丁酸，是一种非蛋白质源氨基酸，其侧链为两个甲基。它在肽链中倾向于诱导螺旋构象并限制骨架的柔性。这种刚性被认为有助于抵抗蛋白酶切割。